AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca's antibody cocktail showed more encouraging results in those testing negative at the time of dosing, suggesting it may be effective on people not already infected.

AstraZeneca Antibody Cocktail Fails to Prevent Covid-19 in Trial. Here's the Good News.

AstraZeneca Plc (NASDAQ: AZN) reported data from the STORM CHASER Phase 3 trial showing that its long-acting antibody (LAAB) combination AZD7442 did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 compared to a placebo. AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to a placebo, which was not statistically significant, the company reported.

AstraZeneca's Antibody Treatment Unsuccessful At Preventing Symptomatic COVID-19 Infection

The monoclonal antibody treatment reduced the risk of developing symptomatic Covid-19 by a statistically insignificant 33% among unvaccinated adults.

AstraZeneca's Covid-19 Antibody Treatment Failed To Prevent Symptoms In Exposed Individuals

AstraZeneca PLC (LON:AZN) announced that the trial for a COVID-19 antibody did not meet its primary goal of preventing symptoms in people exposed to the virus. Participants were 1,121 unvaccinated adults 18 years and over with confirmed exposure to a person with a case of the virus within the previous eight days.

AstraZeneca reports failure in COVID-19 antibody trial on people already exposed to virus

Freeport-McMoRan

Merck

Starbucks

Verizon

West Fraser Timber Co. Ltd.

Walmart

Shares don't always rise, but dividend income is as steady as it gets. These dividend stocks are great long-term, despite recent weaknesses.

7 Dividend Stocks Offering Juicy Yields and Short-Squeeze Potential

The PRAC of the European Medicines Agency (EMA) has advised against giving AstraZeneca's (AZN) Vaxzevria COVID-19 vaccine to people with a history of capillary leak syndrome, a rare blood disorder.

AstraZeneca (AZN) COVID-19 Jab's New Side Effect Stated by EMA

Amgen

BeiGene

Legend Biotech

Sanofi

A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutting-edge treatments more quickly to Chinese patients.

Drug Startups Eye Quicker Profits Under China's New Fast-Track Approvals

BOSTON, June 8, 2021 /PRNewswire/ -- PathAI, a global leader of AI-powered technology applied to pathology, today announced that new data highlighting a quality control tool for HER2 testing in digital pathology images captured in clinical trials will be presented in the American Society of Clinical Oncology (ASCO) Virtual Scientific Program 2021, held from June 4-8, 2021. These results will be shared in the poster presentation, Machine learning models to quantify HER2 for real-time tissue image analysis in prospective clinical trials (Abstract #3061), in the session, Developmental Therapeutics —Molecularly Targeted Agents and Tumor Biology.

PathAI to Present Machine Learning-based Quality Control Tool for HER2 Testing in Breast Cancer at the American Society of Clinical Oncology Virtual Scientific Program 2021

Adobe

Biogen

Domino's Pizza

Illumina

O'Reilly Automotive

Are you looking for stocks that have been beaten up in recent weeks? Here are seven stocks to buy right now at the start of the summer.

7 Beaten-Down Stocks to Buy Right Now for a June Rebound

NetScientific PLC's (LON:NSCI), up 235 at 92p, was the top riser after striking a licensing deal with AstraZeneca PLC (LON:AZN). Its ProAxsis subsidiary is to work with AstraZeneca over the validation and global commercialisation of an assay associated with coronavirus vaccines.

NetScientific tops the risers after deal with AstraZeneca

NetScientific PLC's (LON:NSCI) ProAxsis subsidiary has struck a licensing deal with AstraZeneca PLC (LON:AZN) over the validation and global commercialisation of an assay associated with coronavirus vaccines. The subsidiary of the AIM-listed company will take responsibility for completing the validation and global commercialisation of an enzyme-linked immunosorbent assay (ELISA) developed by an internal research team at AstraZeneca for vaccines associated with SARS-CoV-2, which is the virus associated with COVID-19.

NetScientific's ProAxsis to validate and commercialise AstraZeneca's coronavirus vaccine assay

Astrazeneca (AZN) closed at $56.80 in the latest trading session, marking a +0.98% move from the prior day.

Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know

AstraZeneca Plc's (NASDAQ: AZN) has announced updated results from the PACIFIC Phase 3 trial of Imfinzi (durvalumab), showing survival benefit at five years in patients with unresectable Stage III non-small-cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT). Imfinzi posted an overall survival rate of 43% for Stage III non-small cell lung cancer patients whose tumors can't be removed five years after chemoradiation treatment.

AstraZeneca Unveils 5-Year Survival Data for Imfinzi in Lung Cancer Patients

AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating Lynparza (olaparib) in a subset of early breast cancer patients. Results will be presented at the 2021 American Society of Clinical Oncology Annual Meeting and published in the New England Journal of Medicine.

AstraZeneca, Merck Lynparza Earns Win in Early Breast Cancer, Showing Potential in Post-Surgery Setting

AstraZeneca PLC (LON:AZN) announced it has appointed Aradhana Sarin as an executive director and chief financial officer, effective from 1 August. The appointment is conditional on the success of the US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc., which is expected to complete in the third quarter.

AstraZeneca to appoint new chief financial officer when Alexion acquisition completes

Drugmaker AstraZeneca Plc said on Friday it had appointed Alexion's Aradhana Sarin as its new chief financial officer to succeed Marc Dunoyer who would be taking up a new role within the company.

AstraZeneca names Alexion's Sarin as new finance chief

Novavax

The White House said Thursday that it removed a requirement that is part of the Defense Production Act that gives the U.S. preferential orders for the COVID-19 vaccines developed by AstraZeneca , Novavax Inc. , and Sanofi . None of these shots have been authorized in the U.S., but the change allows the companies to decide which orders, including from other countries, they will fulfill first.

White House to allow AstraZeneca, Novavax, Sanofi to distribute COVID-19 shots how they see fit

Catalent

AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc's (NYSE: EBS) Baltimore plant to a factory owned by Catalent Inc (NYSE: CTLT), the New York Times reported. The company has been on the lookout for an alternative production site since the U.S. government stopped it from using Emergent's Baltimore plant after workers accidentally contaminated a batch of Johnson & Johnson's (NYSE: JNJ) vaccine with ingredients from AstraZeneca's that was also being produced at the time.

AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT

BioNTech SE

Dyadic International Inc., DE

Johnson & Johnson

The party is apparently “On” as far as the developed world's sense of “reopening” is concerned. But the global truth is far removed from this celebration, as less than 20% of the world's population have had access to a vaccine.

The Vaccine Investment Hypothesis, and What's Next (AZN, JNJ, DYAI, BNTX)

Privately-held Proteros biostructures GmbH has signed an agreement with AstraZeneca Plc (NASDAQ: AZN) to jointly discover and develop novel small molecules for the potential treatment of various types of cancer. Under the agreement, AstraZeneca will provide research funding, and Proteros will be eligible for success-based research, development, and commercial milestone payments up to €62 million, as well as tiered royalties on annual net sales.

AstraZeneca, Proteros Team Up To Develop Novel Anti-Cancer Medicines

AstraZeneca Plc (NASDAQ: AZN) has announced a new posthoc analysis of pooled data from the TULIP Phase 3 clinical trials evaluating anifrolumab in patients with moderate to severe systemic lupus erythematosus (SLE). Data were presented at the annual European Congress of Rheumatology (EULAR 2021).

AstraZeneca's Anifrolumab Shows Benefit In Skin, Joint Diseases In Systemic Lupus Erythematosus Patients

MUNICH--(BUSINESS WIRE)--Proteros biostructures GmbH (“Proteros”) today announced that it has signed an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to jointly discover and develop novel small molecules for the potential treatment of various types of cancer. The collaboration brings together Proteros' discovery capabilities which are tailored to unlock even the most technically challenging drug targets with AstraZeneca's expertise in target biology and medicinal chemistry to jointly discove

Proteros Enters Into Oncology Collaboration and License Agreement With AstraZeneca

Alexion Pharma

EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.

EU to decide on Astrazeneca's $39 billion Alexion deal by July 5

GlaxoSmithKline

These pharmaceutical companies might make great long-term additions to your portfolio.

2 Deeply Discounted Dividend Stocks to Buy and Hold Right Now

AstraZeneca Plc's (NASDAQ: AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer. The European Commission has approved the lung cancer drug as an add-on (adjuvant) treatment for adults diagnosed early enough for the tumor to be surgically removed and have a mutation of the EGFR gene.

AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer

News for AstraZeneca Stock (AZN)